Eli Lilly and Company has announced the appointment of Lucas Montarce as its new Executive Vice President and Chief Financial Officer (CFO), effective immediately. Montarce will also join Lilly’s Executive Committee.
Montarce’s Journey at Lilly
Montarce’s journey with Lilly began in 2001 when he took on various finance leadership roles. His impressive career includes serving as Group Vice President, Corporate Controller, and CFO of Lilly Research Laboratories; Vice President, Finance, and CFO of Lilly International; and Global CFO of Elanco Health. Most recently, he was the President and General Manager for the Spain, Portugal, and Greece hub.
Leadership and Vision
David A. Ricks, Lilly’s Chair and CEO, expressed confidence about Montarce’s appointment. “Lucas has demonstrated exceptional leadership in diverse roles. His drive, curiosity, and integrity make him a perfect fit for our next CFO,” Ricks stated.
Montarce himself is excited about the new role. “I am honored to take on this role during such a crucial time for Lilly. I am committed to building on our strong financial foundation and driving continued success as we expand globally,” he said.
About Lilly
Lilly, a global leader in medicine, has been initiating discoveries for nearly 150 years. The company’s medicines impact over 51 million people worldwide, addressing significant health challenges including diabetes, obesity, Alzheimer’s disease, and cancer. Lilly is dedicated to making life better through innovation and accessibility.
Forward-Looking Statements
This announcement contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements reflect Lilly’s current beliefs and expectations but are subject to risks and uncertainties. For more details, see Lilly’s Form 10-K and Form 10-Q filings with the U.S. Securities and Exchange Commission.
